Skip to main content
Back to timeline
Venture CapitalSource publication:

Isomorphic Labs closes a $5 billion Series C to push its AI-designed drug candidates toward clinical trials

Synopsis

Isomorphic Labs announced a $5 billion Series C round co-led by Greenoaks and Sequoia Capital, with new investors including a16z, a continued major investment from Alphabet, and participation from all existing investors. The company says the capital will go toward further developing its proprietary drug-design engine IsoDDE, expanding its internal and partnered candidate portfolio, and building AI infrastructure for translational and clinical development. It also states that internal oncology and immunology programs and partnered projects have produced positive preclinical results, laying the groundwork for entering the clinical stage.

AI-generated editorial illustration: Isomorphic Labs anuncia una ronda de financiación de serie C de 5.000 millones de dólares

Interpretation

Isomorphic Labs has raised a $5 billion Series C, aimed at expanding both its AI drug-design engine and its candidate portfolio. The company had been building candidates through internal and partnered programs in parallel; this round concentrates resources on three lines: the IsoDDE engine, portfolio expansion, and global AI-driven bioengineering infrastructure. The size of the round and the investor list come directly from the company announcement: Greenoaks and Sequoia Capital co-led, new investors including a16z joined, Alphabet continued a major investment, and Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund all participated.

The funds are intended to move candidates into clinical trials, and the company says its internal oncology and immunology programs and partnered projects have generated positive preclinical results. These programs were previously at the preclinical stage, and the announcement frames the round as the basis for entering the clinical stage. This progress is stated by the company itself; the announcement gives no specific program names, molecule counts, preclinical data metrics or trial start dates.

IsoDDE consists of a set of simulation-based AI foundation models designed to operate natively across therapeutic areas and drug modalities, used to design and refine molecules across broad chemical spaces. The company says the breadth and precision of these simulation models raise prediction accuracy to levels close to experimental results. That accuracy statement comes from the company announcement and carries no specific benchmark, dataset or error value.

Perspective

The announcement describes financing and company plans: the funds go to continued development of IsoDDE, expansion of internal and partnered pipelines, and AI infrastructure for translational and clinical development; the programs involved are at the preclinical stage, and the announcement gives no trial start date.

Statements that prediction accuracy approaches experimental results, that reproducible scientific progress is achieved weekly, and that preclinical results are positive are all attributed to the company and its investors, without specific metrics; the announcement also does not specify the order or timing in which programs will enter the clinic.